Professor, Medicine, Tufts Medical Center
Cardiology
Dr. Marc J. Schweiger, MD
|
|
Give Review
Dr. Marc J. Schweiger is an expert in the field of Cardiology. He studied medicine at State University of New York Upstate Medical University. He has 2 awards "Meaningful Use Stage 1 Certification" and "Heart/Stroke Recognition Program". Doctor Marc J. Schweiger, MD is also a published doctor. He has 37 paper published. The most recent paper is: Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clin... He is registered with Medicare and accepts Medicare payments.
Publications
- Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation Acute coronary syndromes patients with left circumflex culprit...
- The impact of the distance from the interventional cardiologist's home to the hospital during off hours.
- Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation Acute coronary syndrome:...
- Patients' and cardiologists' perceptions of the benefits of percutaneous Coronary intervention for stable Coronary disease.
- Door-to-balloon time: are we evaluating the wrong metric?
- One can't judge a stent by its cover.
- Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures.
- Morphology and location of restenosis following bare metal Coronary stenting.
- Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous Coronary intervention.
- Underutilization of evidence-based medications in Acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry.
- Severe anaphylactoid reaction to radiographic contrast media. Recurrences despites premedication with diphenhydramine and prednisone.
- Spontaneous cure of infected left Atrial myxoma following embolization.
- Long-term follow-up and influence of symptom-free interval on restenosis after repeat percutaneous transluminal Coronary angioplasty.
- Sequential and reversible multiple vessel Coronary occlusion following angioplasty.
- Treatment of patients following bypass surgery: a dilemma for the 1990s.
- Hematocrit fluctuations after percutaneous transluminal Coronary angioplasty.
- Ad hoc Coronary intervention.
- Diffuse alveolar hemorrhage after clopidogrel use.
- Coronary angioplasty performed within the thrombolysis in Myocardial Infarction II study.
- Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in Myocardial infarction 10B trial. TIMI 10B I...
- The relation of clinical outcome to dissection and thrombus formation during Coronary angioplasty. Heparin Registry Investigators.
- Determinants of Coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction.
- Factors associated with failure of medical therapy in patients with unstable Angina and non-Q wave myocardial infarction. A TIMI-IIIB database study.
- Comparison of patients with < 60% to > or = 60% diameter narrowing of the myocardial infarct-related Artery after thrombolysis. The TIMI Investigators.
- Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after Coronary angioplasty.
- Early coronary intervention following pharmacologic therapy for Acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience).
- Trends in the use of pharmacotherapies for Acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clin...
- TNK-tissue plasminogen activator compared with front-loaded alteplase in Acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarct...
- Prospective validation of a composite end point in thrombolytic trials of Acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction.
- A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for Acute myocardial infarction: ...
- Prognostic implications of elevated troponin in patients with suspected Acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy.
- Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in Acute myocardial infarction.
- Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneou...
- Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation Acute coronary syndrome: the ANTHEM-TIMI-32 trial.
- Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme.
- High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated Acute coronary syndrome patients--a Pravastatin or Atorvastatin Evalua...
Schools
SUNY Upstate Medical University Syracuse
Boston City Hospital
University Hospital
Procedures Preformed
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Cardiac Myocardial Perfusion Imaging
- View All
Conditions Treated
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Ectasia
- Aortic Valve Disease
- View All
Doctors Specialties
- Cardiology
- Interventional Cardiology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
- Heart/Stroke Recognition Program
Education
-
Boston University Medical Center -
State University of New York Upstate Medical University
Hospital
-
Boston Medical Center
Drug Facts
| NPI NUMBER | 1467550145 | |
| NPPES Provider LastName | SCHWEIGER | |
| NPPES Provider FirstName | MARC | |
| NPPES Provider ZIPCode | 011991619 | |
| NPPES Provider State | MA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 805.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1467550145 |
| Last Name Of The Provider | SCHWEIGER |
| First Name Of The Provider | MARC |
| View All |